This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Joint Corp. (JYNT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of -500% and 2.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $99.52 in the latest trading session, marking a +1.18% move from the prior day.
Merit Medical (MMSI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 4.55% and 0.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
Cardinal Health (CAH) reachead $100.83 at the closing of the latest trading day, reflecting a +0.57% change compared to its last close.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cardinal Health (CAH) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, Cardinal Health (CAH) closed at $96.71, indicating a +0.91% shift from the previous trading day.
Why the Market Dipped But Cardinal Health (CAH) Gained Today
by Zacks Equity Research
In the closing of the recent trading day, Cardinal Health (CAH) stood at $95.84, denoting a +0.44% change from the preceding trading day.
Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings
by Zacks Equity Research
FDA investigations into Cardinal Health's (CAH) China-based syringe manufacturers, Jiangsu Shenli and Jiangsu Caina, reveal significant quality violations, prompting recalls and import alerts.
Why the Market Dipped But Cardinal Health (CAH) Gained Today
by Zacks Equity Research
Cardinal Health (CAH) closed at $95.97 in the latest trading session, marking a +0.59% move from the prior day.
Cardinal Health (CAH) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Cardinal Health (CAH) concluded the recent trading session at $93.74, signifying a -0.38% move from its prior day's close.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cardinal Health (CAH) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Cardinal Health (CAH) concluded the recent trading session at $96.01, signifying a -0.9% move from its prior day's close.
Cardinal Health (CAH) Recalls Kits Containing Shenli's Syringes
by Zacks Equity Research
Cardinal Health (CAH) recalls its procedure kits that contain plastic syringes manufactured by a Chinese manufacturer, Jiangsu Shenli.
Cencora (COR) Stock Nosedives: Here's What Caused the Decline
by Zacks Equity Research
Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.
Cardinal Health (CAH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Cardinal Health (CAH) stood at $101.10, denoting a -1.97% change from the preceding trading day.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Cardinal Health (CAH) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. Gross margins improve. However, the rising cost of products is a concern.
Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance.
Investors Heavily Search Cardinal Health, Inc. (CAH): Here is What You Need to Know
by Zacks Equity Research
Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is What to Know Beyond Why Cardinal Health, Inc. (CAH) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Cardinal (CAH). This makes it worthwhile to examine what the stock has in store.
Compared to Estimates, Cardinal (CAH) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Cardinal (CAH) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.